What Happened

Novo has acquired three non-incretin obesity drug programs from New York biotech Kallyope. The assets include a potential first-in-class peptide (K-554, which is IND-ready), a follow-on small molecule for a novel target, and a small molecule receptor agonist. The deal was confirmed by a Novo spokesperson, though financial terms were not disclosed.

Who Is Affected

Novo's global research and business development teams are directly involved, with Jacob Petersen (head of global research) and Tamara Darrow (head of global business development) announcing the deal via LinkedIn. Kallyope is the seller, having previously outlined K-554's phase 1 plans for 2026. The acquisition impacts Novo's obesity pipeline, which competes with Lilly's offerings.

Market Impact

• Strengthens Novo's obesity pipeline with non-incretin mechanisms, diversifying beyond GLP-1s like semaglutide.
• Follows a $1.4 billion biobucks pact with Orbis Medicines for macrocycle drugs targeting cardiometabolic diseases.
• Comes amid Novo's brand refresh and ongoing competition with Lilly in the obesity market.
• Pipeline setback from ziltivekimab's phase 3 failures may increase focus on obesity acquisitions.

What to Watch

Watch for K-554's phase 1 trial initiation and data readout in the second half of 2026. Monitor Novo's business development activity for further external sourcing of obesity and cardiometabolic assets. Track how this acquisition impacts Novo's pipeline differentiation against Lilly's incretin-based portfolio.

Related coverage

• Lundbeck reportedly seeks to acquire US pharma company Xeris Biopharma
• AVS Bio acquires Cambridge life sciences firm Biorbyt
• Eli Lilly acquires 5-MeO-DMT developer AtaiBeckley for up to $3.8B
• ITM Isotope Technologies Munich SE merges with Telix Pharmaceuticals in $2.35B radiopharma deal